Management of nonalcoholic steatohepatitis: an evidence-based approach

Clin Liver Dis. 2012 Aug;16(3):631-45. doi: 10.1016/j.cld.2012.05.003. Epub 2012 Jun 20.


Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are an increasingly common cause of chronic liver disease in the developed world, with NASH projected to be the leading cause of liver transplantation in the United States by 2020. This review of NASH management addresses current data from the perspective of levels of evidence for therapeutic options in NASH, including lifestyle modification, drug therapies, and bariatric surgery. In particular, behavioral therapies to assist patients in adopting lifestyle changes are highlighted and a research agenda for future NASH management is presented.

Publication types

  • Review

MeSH terms

  • Anti-Obesity Agents / therapeutic use
  • Bariatric Surgery
  • Cognitive Behavioral Therapy
  • Diet, Mediterranean
  • Evidence-Based Medicine*
  • Exercise Therapy
  • Fatty Acids, Omega-3 / therapeutic use
  • Fatty Liver / diet therapy
  • Fatty Liver / drug therapy
  • Fatty Liver / surgery
  • Fatty Liver / therapy*
  • Humans
  • Non-alcoholic Fatty Liver Disease
  • Randomized Controlled Trials as Topic
  • Risk Reduction Behavior
  • Treatment Outcome


  • Anti-Obesity Agents
  • Fatty Acids, Omega-3